SUMMARY The safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine was investigated in 103 infants immunised at 3, 5, and 9 months of age; the infants also received diphtheria, pertussis, and tetanus and polio vaccines. Side effects were compared with 99 matched infants receiving diphtheria, pertussis, and tetanus and polio vaccines only. No serious side effects were observed and the incidence of minor side effects was no greater in the recipients of H influenzae type b conjugate vaccine. Two doses of the vaccine (standard and low)
jtg/ml with the low dose. The geometric mean titre among 21 unimmunised infants at this age was 0-06 ,ug/ml. Both doses therefore generated antibody concentrations likely to be protective after three immunisations. There were no non-responders.
Incorporation of an H influenzae type b conjugate vaccine into the primary immunisation schedule has the potential for preventing over 1000 cases of systemic H influenzae type b disease and 50 deaths each year in the United Kingdom.
Haemophilus influenzae type b causes potentially fatal systemic disease such as meningitis and epiglottitis and other serious infections affecting soft tissues, joints, and lungs. Recent studies' 2 suggest that the incidence of H influenzae type b disease in the United Kingdom is higher than previously reported. 3 The polyribosyl-ribitol phosphate capsule, which is specific to serotype b H influenzae organisms, is a major virulence determinant. 
Results
The vaccine was well tolerated and highly immunogenic. After three immunisations, the 10 tg doses resulted in a rise in geometric mean serum antipolyribosyl-ribitol phosphate antibody titre from 0*11 at 3 months to 26-4 gig/ml at 10 months of age. The 2 gig doses generated lower responses at 10 months (p=0-007) although the geometric mean titre rose from 0-11 to 14-6 gig/ml, and at both doses all infants achieved greater than four fold increases in antibody titre and 98% achieved values above 1-0 gig/ml (figs 1 and 2).
The 10 gig dose resulted in significant increases in This and even higher estimatesl of attack rates from other regions in this country make a compelling case for considering how active immunisation might be successfully implemented. The availability of safe, immunogenic, and protective conjugate vaccines strengthens the argument that wider intervention studies should proceed in the United Kingdom.
